ACT vs RYAN: Enact and Ryan Specialty Group compared
The short version
From the latest prices and each company's SEC filings. Who's ahead on each measure, not which to buy.
- Ryan Specialty Group is the larger company, worth $10.9B, about 1.7 times Enact.
- Ryan Specialty Group grew revenue faster over the last year (+7.4% vs +4.1%).
- Enact keeps more of each dollar of revenue as operating profit (69.1% vs 15.1%).
- On earnings, Enact is the cheaper stock (10.0x vs 50.1x).
Side by side
The stronger figure is shaded where higher (or, for valuation multiples, lower) reads as better. How the implied growth works.
| Measure | ACT | RYAN |
|---|---|---|
| Market cap | $6.5B | $10.9B |
| Share price | $45.97 | $37.01 |
| Revenue (last fiscal year) | $1.2B | $3.0B |
| Free cash flow (last fiscal year) | — | $641M |
| Revenue growth, last year | +4.1% | +7.4% |
| Revenue growth per year, last 5 fiscal years | +2.5% | +20.2% |
| Operating margin | 69.1% | 15.1% |
| Net margin | 54.5% | 3.1% |
| Return on equity | 12.7% | 19.4% |
| P/E (trailing) | 10.0x | 50.1x |
| Price / free cash flow | 8.93x | 18.8x |
| EV / EBITDA | — | 33.3x |
| FCF growth the price implies | — | 2.8% |
| Dividend yield | 1.8% | 1.2% |
| Debt / equity | 0.29x | 21.5x |
| Fundamental grade | B | D |
| Superinvestors holding it | 2 | 3 |
| Insider purchases, last 12 months | 0 | 2 |
Results from SEC filings
Revenue and free cash flow by fiscal year, from each company's 10-K filings.
Enact
| Year | Revenue | Free cash flow | Op. margin |
|---|---|---|---|
| 2021 | $1.1B | — | 62.2% |
| 2022 | $1.1B | — | 82.0% |
| 2023 | $1.2B | — | 73.8% |
| 2024 | $1.2B | — | 73.1% |
| 2025 | $1.2B | — | 69.5% |
Ryan Specialty Group
| Year | Revenue | Free cash flow | Op. margin |
|---|---|---|---|
| 2021 | $1.4B | -$70M | 13.0% |
| 2022 | $1.7B | $328M | 16.9% |
| 2023 | $2.0B | $477M | 17.7% |
| 2024 | $2.5B | $515M | 17.4% |
| 2025 | $3.0B | $641M | 16.5% |
Where the revenue comes from
Enact
No segment breakdown reported.
Ryan Specialty Group · by products, 2025
Wholesale Brokerage$1.6B53%
Underwriting Management$1.0B34%
Binding Authority$370M12%
Compare them in fullFifteen years of statements, quarterly results, DCF and IRR models, and any number of peers side by side.
Open ACT in InvestinglyQuestions
Which is bigger, Enact or Ryan Specialty Group?
Ryan Specialty Group (RYAN), at $10.9B against $6.5B.
Is ACT or RYAN cheaper?
By trailing P/E, Enact (10.0x) is cheaper than Ryan Specialty Group (50.1x). A lower multiple can also mean the market expects less growth.
Which grows faster, ACT or RYAN?
Ryan Specialty Group: revenue grew +7.4% over the last year, against +4.1%.
Prices and ratios as of the last daily update; statements from SEC filings. Information only, not investment advice.